Inurosu Gold 20 Capsule is a combination medication containing Aspirin (75 mg), Rosuvastatin (20 mg), and Clopidogrel (75 mg), designed to provide comprehensive cardiovascular protection. Aspirin acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase, thereby reducing thromboxane A2 production and preventing platelet aggregation. Clopidogrel, another antiplatelet agent, selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor, further reducing platelet activation and aggregation. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby contributing to the reduction of atherosclerotic plaque formation. This combination is primarily indicated for the prevention of atherothrombotic events in patients with established cardiovascular disease or those at high risk, including individuals with a history of myocardial infarction, stroke, or peripheral arterial disease. The synergistic action of these agents helps in reducing the risk of recurrent cardiovascular events by addressing multiple pathophysiological mechanisms simultaneously. Inurosu Gold 20 Capsule should be used under medical supervision, with careful monitoring for potential adverse effects such as bleeding, liver enzyme abnormalities, and muscle-related symptoms. It is contraindicated in patients with active bleeding, severe liver impairment, or hypersensitivity to any component.